Bora Makes Strategic Investment in Tanvex to Combine Biomanufacturing
Bora’s Board of Directors has approved a deal whereby Bora Biologics will combine its biomanufacturing capabilities with those of Tanvex, a biopharma focused on biosimilars that also provides CDMO services. The deal, which is expected to close in the first quarter of 2025, will bring together Bora’s CDMO capabilities and expertise from Tanvex, as well as its FDA-approved commercial-scale facility in San Diego. Upon closing, Bora will hold around 30% of Tanvex’s total outstanding shares, and Bobby Sheng, Bora Group’s Chairman and CEO, will chair the combined organization.
This latest announcement follows the closing of Bora’s acquisition of Emergent’s sterile fill/finish facility in Baltimore-Camden, Maryland, and the acquisition of Upsher-Smith’s small molecule business, which is based around two sites in Minnesota.
Bora Pharmaceuticals Co., Ltd, today announced that its Board of Directors has approved a strategic investment into Tanvex Biopharma Co., Ltd, whereby Bora Biologics, a wholly owned subsidiary of Bora and specialist large molecule CDMO, and Tanvex will combine their biomanufacturing facilities to create a global solution for biologics development and supply. The investment will bring together Bora’s extensive CDMO capabilities and total service culture with Tanvex’s scale, development expertise and USFDA-approved commercial-scale facility in San Diego, California, and, upon completion, the appointment of Mr. Bobby Sheng, Chairman and CEO of the Bora Group, as Chairman of the merged organization. Upon completion of the transaction, which is expected in Q1 of 2025, Bora will hold approximately 30.5% of Tanvex’s total outstanding shares based on current shareholding structure, becoming the single largest shareholder of Tanvex.
Bora Pharmaceuticals is a leading global CDMO with 10 state-of-the-art factories around the world. Upon completion, the company will closely collaborate with Tanvex to leverage its global CDMO operations and capabilities to provide comprehensive solutions to biologics customers, including Bora ‘s new fill/finish capabilities in Maryland, USA. Tanvex has created a strong biologics development and manufacturing operations in both USA and Taiwan. Combined, these capabilities offer a global development and manufacturing platform to biologics customers both in US and Asia. Tanvex brings over 100,000 sq. ft. of biomanufacturing space and 1,000 liter bioreactors, which complement Bora’s 500-liter bioreactors to provide a scalable service offering.
“This strategic investment focuses on both parties’ shared vision for the biologics CDMO business,” said Bobby Sheng. “It combines Bora’s strong reputation, industry leading quality and global operational resources with Tanvex’s established USFDA-approved commercial scale biologics facility and biosimilar expertise in San Diego. This partnership will enable the combined entity to rapidly respond to evolving industry demands and policy developments, such as the BIOSECURE Act in the US, and capitalize on new opportunities in onshoring, friendshoring, and the growing CDMO demands driven by these policy changes.”
Henry Chen, Chairman and CEO of Tanvex, added, “Tanvex has been dedicated to the development and manufacturing of biologics since its inception and now offers an integrated suite of services from early stage non-GMP pre-clinical development to commercial stage CGMP manufacturing. The strategic investment by Bora presents an optimal opportunity combine our strengths with Bora’s proven success in building a global CDMO platform characterized by exceptional quality, excellent manufacturing track-record and strong customer relationships.”
This strategic investment marks Bora Group’s third major announcement in 2024 following its recent acquisition of Upsher Smith’s extensive small molecule operations and the acquisition of a sterile injectable manufacturing facility in Baltimore-Camden, Maryland, which strengthened Bora’s fill/finish capabilities, which are essential for large molecule CDMO services and will help provide an integrated solution to the new customers.
For more, please find the original story source here.
